Genomic deletions explain the generation of alternative BRAF isoforms conferring resistance to MAPK inhibitors in melanoma

Abstract excerpt

Resistance to MAPK inhibitors (MAPKi), the main cause of relapse in BRAF-mutant melanoma, is associated with the production of alternative BRAF mRNA isoforms (altBRAFs) in up to 30% of patients receiving BRAF inhibitor monotherapy. These altBRAFs have been described as being generated by alternative pre-mRNA splicing, and splicing modulation has been proposed as a therapeutic strategy to overcome resistance. In...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Cancer Mechanisms and Therapy
• Share to Cutaneous Melanoma Detection and Management
• Share to Melanoma and MAPK Pathways